5月31日,《每日经济新闻》记者注意到,在2026年美国临床肿瘤学会(ASCO)年会上,康方生物(HK09926,股价118.10港元,市值1088亿港元)PD-1/VEGF双抗依沃西联合化疗对比替雷利珠单抗联合化疗,一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)III期HARMONi-6/AK112-306研究的OS(总生存期)显著阳性结果揭晓。 HARMONi-6研究共入组532例受试者,...
Source Link5月31日,《每日经济新闻》记者注意到,在2026年美国临床肿瘤学会(ASCO)年会上,康方生物(HK09926,股价118.10港元,市值1088亿港元)PD-1/VEGF双抗依沃西联合化疗对比替雷利珠单抗联合化疗,一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)III期HARMONi-6/AK112-306研究的OS(总生存期)显著阳性结果揭晓。 HARMONi-6研究共入组532例受试者,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.